Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
NCT02744612Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jun 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in Hodgkin lymphoma (HL), sponsored by City of Hope. Started Jun 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02744612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744612.